Cyclophosphamide
Non-Small Cell Lung Carcinoma
Explore 1,128 assets in Non-Small Cell Lung Carcinoma →Floatz Rating
B60/100
Confidence
Indicative
Sponsor
University of Pennsylvania
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07116057CT.gov MOv19-BBz CAR T Cells in FRa+ Cancers | — | Recruiting | — | — | — |
NCT07105176CT.gov HS-IT101 Injection for Advanced NSCLC | — | Not Yet Recruiting | — | — | — |
NCT06538012CT.gov TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer | — | Recruiting | — | — | — |
NCT06253520CT.gov Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer | — | Active Not Recruiting | — | — | — |
NCT04102436CT.gov Non-Viral TCR Gene Therapy | — | Withdrawn | — | — | — |
NCT05681780CT.gov Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC | — | Recruiting | — | — | — |
NCT05492682CT.gov START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer | — | Recruiting | — | — | — |
NCT05566223CT.gov CISH Inactivated TILs in the Treatment of NSCLC | — | Withdrawn | — | — | — |
NCT05334329CT.gov Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors | — | Active Not Recruiting | — | — | — |
NCT05451849CT.gov A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | — | Active Not Recruiting | — | — | — |
Show 34 more trialsShow fewer
NCT05395052CT.gov FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors | — | Terminated | — | — | — |
NCT05296564CT.gov Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers | — | Recruiting | — | — | — |
NCT05269381CT.gov Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05195619CT.gov Personalized DC Vaccines in Non Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT05061017CT.gov Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC) | — | Completed | — | — | — |
NCT04639245CT.gov Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer | — | Terminated | — | — | — |
NCT04282044CT.gov Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies | — | Recruiting | — | — | — |
NCT04596033CT.gov TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | — | Terminated | — | — | — |
NCT04025216CT.gov A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers | — | Terminated | — | — | — |
NCT03907852CT.gov Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer | — | Active Not Recruiting | — | — | — |
NCT03841110CT.gov FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03836352CT.gov Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03412877CT.gov Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer | — | Recruiting | — | — | — |
NCT03623750CT.gov E GFR TKI and EGF-P TI C Ombination in EGFR mutA nt NSCL C | — | Completed | — | — | — |
NCT03574649CT.gov QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer | — | Withdrawn | — | — | — |
NCT03169738CT.gov QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors | — | Withdrawn | — | — | — |
NCT03215810CT.gov Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT03029273CT.gov NY-ESO-1 TCR （TAEST16001）for Patients With Advanced NSCLC | — | Unknown | — | — | — |
NCT02419170CT.gov Mature Dendritic Cell Vaccination Against Unique Immunogenic Peptides in Patients With Non Small Cell Lung Cancer (NSCLC) | — | Withdrawn | — | — | — |
NCT02650635CT.gov TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors | — | Terminated | — | — | — |
NCT02419495CT.gov Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | — | Terminated | — | — | — |
NCT02408016CT.gov Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma | — | Terminated | — | — | — |
NCT02133196CT.gov T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT02117024CT.gov A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT02049151CT.gov Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer | — | Terminated | — | — | — |
NCT01967823CT.gov T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer | — | Completed | — | — | — |
NCT01909752CT.gov Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT01015443CT.gov Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population | — | Terminated | — | — | — |
NCT00960115CT.gov Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy | — | Completed | — | — | — |
NCT00409188CT.gov Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START) | — | Completed | — | — | — |
NCT00157196CT.gov Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease | — | Completed | — | — | — |
NCT00228358CT.gov Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine | — | Completed | — | — | — |
NCT00089726CT.gov A Cancer Vaccine (CG8123) Given With and Without Cyclophosphamide for Advanced Stage Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT00157209CT.gov Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Non-Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cyclophosphamide (this asset) | University of Pennsylvania | P3 | B · 60 |
| Necitumumab | Jonsson Comprehensive Cancer Center | P3 | BBB |
| Glumetinib | Shanghai JMT-Bio Inc. | P3 | BBB |
| Veliparib | AbbVie | P3 | BBB |
| d-0316 | Betta Pharmaceuticals Co., Ltd. | P2/3 | BBB |
| Icotinib | The First Affiliated Hospital of Guangzhou Medical University | P4 | BBB |
| Zoledronate | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | P4 | BBB |
| Onartuzumab | Hoffmann-La Roche | P3 | BBB |
| Avitinib | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | P3 | BBB |
+42 more in the Non-Small Cell Lung Carcinoma cohort
Other indications for Cyclophosphamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| Mycosis Fungoides | — | P4 | BBB · 78 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cyclophosphamide in Non-Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cyclophosphamide-non-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →